Skip to main content

CRISPR Therapeutics Expands Research and Manufacturing Facilities

Published 8/10/2020
CRISPR Therapeutics & Breakthrough Properties - 105 West First Street

CRISPR Therapeutics signed a full-building lease in July of 2020 for a 263,500-sf facility in Boston's Seaport district. Breakthrough Properties is the developer for the project, which was designed by Payette to provide best-in-class laboratory environments for life science research. Both LEED Gold and Fitwel certification will be sought for the structure, which will offer multiple amenities including outdoor terraces and a fitness center. Ground was broken on the facility in spring of 2020 and completion is expected in early 2022. 

CRSIPR Therapeutics is also developing a cell therapy manufacturing center in Framingham. The project includes the internal build-out of an existing structure to support clinical and commercial production of investigational cell therapy product candidates. The GMP facility will be constructed to meet the regulations and guidelines of the U.S. Food and Drug Administration and the European Medicines Agency.

Headquartered in Zug, Switzerland, CRISPR Therapeutics is a leading gene-editing company focused on developing transformative medicines for serious diseases.

Organization Project Role